Long-term safety, tolerability, and efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes

Diabetology International

Volumn 2, Issue 2, 2011, Pages 94-105

  Odawara, Masato ^a   Kadowaki, Takashi ^b   Tajima, Naoko ^c   Nishii, Mikio ^d   Taniguchi, Tadaaki ^e   Ferreira, Juan Camilo Arjona ^f  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d ONO PHARMACEUTICAL CO   (Japan)

^e Merck Sharp Dohm Res Labs Japan   (Japan)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

DPP 4; Incretins; Sitagliptin; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; METFORMIN; SITAGLIPTIN; SULFONYLUREA;

ABDOMINAL PAIN; ACUTE HEART FAILURE; ACUTE HEART INFARCTION; ADULT; ARTICLE; BACKACHE; BODY WEIGHT; BRAIN INFARCTION; CATARACT; COLON POLYP; CONSTIPATION; DEHYDRATION; DIABETIC DIET; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EXERCISE; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; HYPESTHESIA; HYPOGLYCEMIA; ISCHEMIC COLITIS; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROMA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPTIC ISCHEMIC NEUROPATHY; PRIORITY JOURNAL; RHINOPHARYNGITIS; SIDE EFFECT; SPINE FRACTURE; STOMACH CANCER; TREATMENT DURATION; UNCONSCIOUSNESS; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; VOMITING;

EID: 84862859373     PISSN: 21901678     EISSN: 21901686     Source Type: Journal    
DOI: 10.1007/s13340-011-0029-8     Document Type: Article

References (29)

1. DeFronzo RA. Lilly Lecture 1986: the triumvirate: B-cell, muscle, liver: a collusion responsible for type 2 diabetes. Diabetes. 1988; 37: 667-87.
2. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2009; 32: 193-203.
3. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002; 287: 360-72.
4. Barnett A, Allsworth J, Jameson K, Mann R. A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies. Curr Med Res Opin. 2007; 23: 1493-507.
5. Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology. 2002; 122: 531-44.
6. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006; 91: 4612-9.
7. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C. Emerging role of dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes. Vasc Health Risk Manag. 2008; 4: 753-68.
8. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the dipeptidyl peptidase-4 inhibitor, sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006; 29: 2632-7.
9. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor Sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2009; 29: 2638-43.
10. Goldstein BJ, Feingold MN, Lunceford JK, Johnson J, Williams-Herman DE, for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007; 30: 1979-87.
11. Hanefeld M, Herman GA, Wu M, Mickel C, Sanchez M, Stein PP. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin. 2007; 23: 1329-39.
12. Hermansen K, Kipnes M, Lou E, Fanurik D, Khatami H, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007; 9: 733-45.
13. Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006; 49: 2564-71.
14. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added on ongoing pioglitazone therapy in patients with type 2 diabetes; a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006; 28: 1556-68.
15. Scott R, Wu M, Sanchez M, Stein PP, et al. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract. 2007; 61: 171-80.
16. Fukushima M, Suzuki H, Seino Y. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract. 2004; 66: S37-43.
17. Kuroe A, Fukushima M, Usami M, et al. Impaired beta-cell function and insulin sensitivity in Japanese subjects with normal glucose tolerance. Diabetes Res Clin Pract. 2003; 59: 71-7.
18. Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009; 301: 2129-40.
19. Kadowaki T, Miyake Y, Hagura R, et al. Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. Diabetologia. 1984; 26: 44-9.
20. Nonaka K, Kakikawa T, Sato A, et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2008; 79: 291-8.
21. Iwamoto Y, Taniguchi T, Nonaka K, et al. Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Endocr J. 2010; 57: 383-94.
22. Iwamoto Y, Tajima N, Kadowaki T, et al. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes Obes Metab. 2010; 12: 613-22.
23. Japan Diabetes Society. The guideline for the treatment of diabetes. Tokyo: Japan Diabetes Society, 2008-2009.
24. The Committee of Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Jpn Diabetes Soc. 2010; 53: 450-67.
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28: 412-9.
26. Wook K, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008; 60: 470-512.
27. Williams-Herman D et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10, 246 patients with type 2 diabetes. BMC Endocr Disord. 2010; 10: 7.
28. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007; 298(2): 194-206.
29. Xu L, Man CD, Charbonnel B, et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach. Diabetes Obes Metab. 2008; 10: 1212-20.